- 1. What are your biggest concerns with RWE as a source of evidence for causal inference?
 - a) No concerns, it helps address gaps from clinical trials
 - b) Concerns with confounding
 - c) Concerns with acceptability by decision makers
 - d) Concerns with lack of fit-for-purpose data sources
 - e) Other concerns

- 2. How familiar are you with causal inference methods for real world data?
 - a) Not at all familiar
 - b) Somewhat familiar
 - c) Very familiar with traditional methods
 - d) Very familiar with traditional and doubly-robust machines learning based methods such as augmented inverse probability of treatment weighting and targeted maximum likelihood estimation (A-IPTW/TMLE)

- 3. What is the key feature of doubly robust methods based on machine learning?
 - a) Only one model fits (among treatment/censoring mechanism, and outcome regression) needs to be correct
 - b) Super learning ends up with better algorithm for fitting these regressions than any one algorithm
 - c) Doubly-robust ML-based methods have a higher likelihood of getting a correct effect estimate
 - d) All of the above

- 4. What difficulties have you experienced in submitting findings based on novel advanced methods to regulatory/HTA bodies?
 - a) Explaining the methods
 - b) Implementing the methods in suitable way, due to various choices that need to be made
 - c) Providing supporting evidence for the methods/real world use-cases
 - d) Demonstrating superiority of the methods
 - e) Other